Panobinostat
Carcinoma, Large Cell
PfizerSmall moleculePhase 3Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Carcinoma, Large Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Crizotinib SWOG Cancer Research Network | Phase 2 | B |
Eloxatin Korean South West Oncology Group | Phase 2 | CCC |
cp-751,871 Pfizer | Phase 3 | CCC |
Dacomitinib National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Panobinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →